Betta Pharmaceuticals (300558.SZ) Earnings Analysis
Betta Pharmaceuticals (300558.SZ) next reports earnings on 2026-08-21, consensus EPS 0.12 CNY. Last quarter (2026-04-23) it missed with EPS 0.24 CNY vs 0.45 CNY est (-46.7%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E 58.02.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 300558.SZ next report earnings?
| Next earnings date | 2026-08-21 |
|---|---|
| Consensus EPS estimate | 0.12 CNY |
| Revenue estimate | 1.02B |
300558.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-23 | 0.24 CNY | 0.45 CNY | -46.7% | Miss |
| 2025-08-19 | 0.1 CNY | 0.39 CNY | -74.4% | Miss |
| 2025-04-17 | -0.03 CNY | 0.38 CNY | -107.9% | Miss |
| 2024-10-28 | 0.46 CNY | 0.22 CNY | +109.1% | Beat |
| 2024-08-05 | 0.54 CNY | 0.19 CNY | +184.2% | Beat |
Beat rate: 2/5 (40%) over reported quarters with consensus data.
300558.SZ valuation and analyst view
| Trailing P/E | 58.02 |
|---|---|
| Trailing EPS | 1.047 CNY |
| Price / book | 3.77 |
| Dividend yield | 0.25% |
| Market cap | 25.54B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Betta Pharmaceuticals (300558.SZ)'s next earnings date?
Betta Pharmaceuticals is next scheduled to report on 2026-08-21, with a consensus EPS estimate of 0.12 CNY and revenue estimate of 1.02B.
Did 300558.SZ beat earnings last quarter?
In its 2026-04-23 report, 300558.SZ posted EPS of 0.24 CNY versus a 0.45 CNY estimate — a miss of 46.7%.
What is 300558.SZ's earnings track record?
Over the last 5 reported quarters with consensus data, 300558.SZ beat estimates 2 times (40%).
What is 300558.SZ's current P/E ratio and EPS?
300558.SZ trades at a trailing P/E of 58.02 on trailing EPS of 1.0471817487018091 CNY.
What do analysts rate 300558.SZ?
300558.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.